Identification of a novel cardenolicle (2′-oxovoruscharin) from Calotropis procera and the hemisynthesis of novel derivatives displaying potent in vitro antitumor activities and high in vivo tolerance: Structure-activity relationship analyses

Journal of Medicinal Chemistry

Volumn 48, Issue 3, 2005, Pages 849-856

  Van Quaquebeke, Eric ^a   Simon, Gentiane ^a   André, Aurélie ^a   Dewelle, Janique ^a   El Yazidi, Mohamed ^a   Bruyneel, Frederic ^a   Tuti, Jerome ^a   Nacoulma, Odile ^b   Guissou, Pierre ^c   Decaestecker, Christine ^d   Braekman, Jean Claude ^d   Kiss, Robert ^d   Darro, Francis ^a  

^a Unibioscreen SA   (Belgium)

^b UNIVERSITÉ DE OUAGADOUGOU   (Burkina Faso)

^c Université Libre de Bruxelles ^*  (Burkina Faso)

^d UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ANTINEOPLASTIC AGENT; CALOTROPIS PROCERA EXTRACT; CARDENOLIDE DERIVATIVE; DOXORUBICIN; ETOPOSIDE; IRINOTECAN; METHANOL; OXALIPLATIN; PACLITAXEL; VINCRISTINE; 2'' OXOVORUSCHARIN; 2''-OXOVORUSCHARIN; 7-ETHYL-10-HYDROXYCAMPTOTHECIN; CAMPTOTHECIN; CARDENOLIDE; DRUG DERIVATIVE; PLATINUM COMPLEX; THIAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CALOTROPIS; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG IDENTIFICATION; DRUG POTENCY; DRUG SYNTHESIS; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MEDICINAL PLANT; MOUSE; NONHUMAN; STRUCTURE ACTIVITY RELATION; ANIMAL; BRAIN CORTEX; CELL PROLIFERATION; CHEMISTRY; DRUG EFFECT; DRUG RESISTANCE; DRUG SCREENING; ISOLATION AND PURIFICATION; MAXIMUM TOLERATED DOSE; MULTIDRUG RESISTANCE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; SWINE; SYNTHESIS; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CALOTROPIS; CAMPTOTHECIN; CARDENOLIDES; CELL LINE, TUMOR; CELL PROLIFERATION; CEREBRAL CORTEX; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; ETOPOSIDE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MAXIMUM TOLERATED DOSE; MICE; NA(+)-K(+)-EXCHANGING ATPASE; ORGANOPLATINUM COMPOUNDS; PACLITAXEL; STRUCTURE-ACTIVITY RELATIONSHIP; SWINE; THIAZOLES;

EID: 20044369153     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm049405a     Document Type: Article

References (59)

1. Nagaty, H. F.; Rifaat, M. A.; Morsy, T. A. The latex of Calotropis procera (family: Asclepiadaceae), a new substances having an ascaricidal effect in-vitro. J. Egypt. Med. Assoc. 1959, 42, 563-566.
2. Sharma, P.; Sharma, J. D. In-vitro schizonticidal screening of Calotropis procera. Fitoterapia 2000, 71, 77-79.
3. Ali, N. A.; Julich, W. D.; Kusnick, C.; Lindequist, U. Screening of Yemeni medicinal plants for antibacterial and cytotoxic activities. J. Ethnopharmacol. 2001, 74, 173-179.
4. Larhsini, M.; Oumoulid, L.; Lazrek, H. B.; Wataleb, S.; Bousaid, M.; Bekkouche, K.; Jana, M. Antibacterial activity of some Moroccan medicinal plants. Phytother. Res. 2001, 15, 250-252.
5. Al-Qarawi, A. A.; Mahmoud, O. M.; Sobaih Haroun, E. M.; Adam, S. E. A preliminary study on the anthelmintic activity of Calotropis procera latex against Haemonchus contortus infection in Najdi sheep. Vet. Res. Commun. 2001, 25, 61-70.
6. Moursy, L. E. Insecticidal activity of Calotropis procera extracts of the flesh fly, Sarcophaga haemorrhoidalis fallen. J. Egypt. Soc. Parasitol. 1997, 27, 505-514.
7. Kumar, V. L.; Basu, N. Antiinflammatory activity of the latex of Calotropis procera. J. Ethnopharmcol. 1994, 44, 123-125.
8. Singh, H.; Kumar, S.; Dewan, S.; Kumar, V. L. Inflammation induced by latex of Calotropis procera - a new model to evaluate antiinflammatory drugs. J. Pharmacol. Toxicol. Methods 2000, 43, 219-224.
9. Kumar, S.; Dewan, S.; Sangraula, H.; Kumar, V. L. Antidiarrhoel activity of the latex of Calotropis procera. J. Ethnopharmacol. 2001, 76, 115-118.
10. Markouk, M.; Bekkouche, K.; Larhsini, M.; Bousaid, M.; Lazrek, H. B.; Jana, M. Evaluation of some Moroccan medicinal plant extracts for larvicidal activity. J. Ethnopharmacol. 2000, 73, 293-297.
11. Smit, H. F.; Woerdenbag, H. J.; Singh, R. H.; Meulenbeld, G. J.; Labadie, R. P.; Zwaving, J. H. Ayurvedic herbal drugs with possible cytostatic activity. J. Ethnopharmacol. 1995, 47, 75-84.
12. Dewan, S.; Sangraula, H.; Kumar, V. L. Preliminary studies on the analgesic activity of latex of Calotropis procera. J. Ethnopharmacol. 2000, 73, 307-311.
13. Ansari, S. H.; Ali, M. Norditerpenic esters and pentacyclic triterpenoids from root bark of Calotropis procera (Ait) R. Br. Pharmazie 2001, 56, 175-177.
14. Gallegos Olea, R. S.; Oliveira, A. V.; Silveira, L. M.; Silveira, E. R. Organic carbonate from Calotropis procera leaves. Fitoterapia 2002, 73, 263-265.
15. Kumar Dubey, V.; Jagannadham, M. V. Procerain, a stable cysteine protease from the latex of Calotropis procera. Phytochemistry 2003, 62, 1057-1071.
16. Shivkar, Y. M.; Kumar, V. L. Histamine mediates the proinflammatory effect of latex of Calotropis procera in rats. Mediators Inflamm. 2003, 12, 299-302.
17. Mossa, J. S.; Tariq, M.; Mohsin, A.; Ageel, A. M.; al-Yahya, M. A.; al-Said, M. S.; Rafatullah, S. Pharmacological studies on aerial parts of Calotropis procera. Am. J. Chin. Med. 1991, 19, 223-231.
18. Erdman, M. D. Nutrient and cardenolide composition of unextracted and solvent-extracted Calotropis procera. J. Agric. Food Chem. 1983, 31, 509-513.
19. Radford, D. J.; Gillies, A. D.; Hinds, J. A.; Duffy, P. Naturally occurring cardiac glycosides. Med. J. Aust. 1986, 144, 540-544.
20. Dmitrieva, R.; Doris, P. A. Cardiotonic steroids: potential endogenous sodium pump ligands with diverse function. Exp. Biol. Med. 2002, 227, 561-569.
21. Schoner, W. Endogenous cardiac glycosides, a new class of steroid hormones. Eur. J. Biochem. 2002, 269, 2440-2448.
22. Haux, J. Digitoxin is a potential anticancer agent for several types of cancer. Med. Hypoth. 1999, 53, 543-548.
23. 2+ increases and apoptosis in androgen-independent, metastatic human prostate adenocarcinoma cells. Cancer Res. 2000, 60, 3807-3812.
24. 2-terminal kinase. Cancer Res. 2000, 60, 3838-3847.
25. Stenkvist, B. Cardenolides and cancer. Anti-Cancer Drugs 2001, 12, 635-636.
26. Crout, D. H. G.; Hassall, C. H.; Jones, T. L. Cardenolides. Part VI. Uscharidin, Calotropin, and Calotoxin. J. Chem. Soc. 1964, 2187-2194.
27. Cheung, H. T. A.; Nelson C. J. Cardenolides Glycosides with 5,6-Unsaturation from Asclepias vestita J. Chem. Soc., Perkin Trans. 1 1989, 1563-1570.
28. Cheung, H. T. A.; Chiu, F. C. K.; Watson, T. R.; Wells, R. S. Cardenolides glycosides of the asclepiadaceae. New glycosides from Asclepias fructicosa and the stereochemistry of uscharin, voruscharin, and calotoxin. J. Chem. Soc., Perkin Trans. 1 1983, 2827-2835.
29. Van Quaquebeke, E.; Braekman, J.-C.; Simon, G.; Guissou, P.; Nacoulma, O. G.; Dewelle, J.; Darro, F.; Kiss, R. EP 1408043, 2004.
30. Camby, I.; Salmon, I.; Danguy, A.; Pasteels, J. L.; Brotchi, J.; Martinez, J.; Kiss, R. Influence of gastrin on human astrocytic tumor cell proliferation. J. Natl. Cancer Inst. 1988, 88, 594-600.
31. Joseph, B.; Darro, F.; Behard, A.; Lesur, B.; Collignon, F.; Decaestecker, C.; Frydman, A.; Guillaumet, G.; Kiss, R. 3-Aryl-2-quinolone derivatives: synthesis and characterization of in vitro and in vivo antitumor effects with emphasis on a new therapeutical target connected with cell migration. J. Med. Chem. 2002, 45, 2543-2555.
32. Malonne, H.; Farinelle, S.; Decaestecker, C.; Gordower, L.; Fontaine, J.; Chaminade, F.; Saucier; J. M.; Atassi, G.; Kiss, R. In vitro and in vivo pharmacological characterizations of the antitumor properties of two new olivacine derivatives, S16020-2 and S30972-1. Clin. Cancer Res. 2000, 6, 3774-3782.
33. Langlois, N.; Rojas-Rousseau, A.; Gaspard, C.; Werner, G. H.; Darro, F.; Kiss, R. Synthesis and cytotoxicity on sensitive and doxorubicin-resistant cell lines of new pyrrolo[2,1-c][1,4]benzodiazepines related to anthramycin. J. Med. Chem. 2001, 44, 3754-3757.
34. Delfourne, E.; Darro, F.; Bontemps-Subielos, N.; Decaestecker, C.; Bastide, J.; Frydman, A.; Kiss, R. Synthesis and characterization of the antitumor activities of analogues of meridine a marine pyridoacridine alkaloid. J. Med. Chem. 2001, 44, 3275-3282.
35. Delfourne, E.; Darro, F.; Portefaix, P.; Galaup, C.; Bayssade, S.; Bouteille, A.; Le Corre, L.; Bastide, J.; Collignon, F.; Lesur, B.; Frydman, A.; Kiss, R. Synthesis and in vitro antitumor activity of novel ring D analogues of the marine pyridoacridine ascididemin: structure-activity relationship. J. Med. Chem. 2002, 45, 3765-3771.
36. Delfourne, E.; Kiss, R.; Le Corre, L.; Dujols, F.; Bastide, J.; Collignon, F.; Lesur, B.; Frydman, A.; Darro, F. Synthesis and in vitro antitumor activity of phenanthrolin-7-one derivatives, analogues of the marine pyridoacridine alkaloids ascididemin and meridine: structure-activity relationship. J. Med. Chem. 2003, 46, 3536-3545.
37. Lesueur-Ginot, L.; Demarquay, D.; Kiss, R.; Kasprzyk, P. G.; Dassonneville, L.; Bailly, C.; Camara, J.; Lavergne, O.; Bigg, D. C. Homocamptothecin, an E-ring modified camptothecin with enhanced lactone stability, retains topoisomerase I-targeted activity and antitumor properties. Cancer Res. 1999, 59, 2939-2943.
38. +-ATPase. Pharmazie 1992, 47, 691-697.
39. Paull, K. D.; Shoemaker, R. H.; Hodes, L.; Monks, A.; Scudiero, D. A.; Rubinstein, L.; Plowman, J.; Boyd, M. R. Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J. Natl. Cancer Inst. 1989, 81, 1088-1092.
40. Pauwels, O.; Kiss, R. Characterization of cross-resistance expressed by 12 chemoresistant cancer cell lines to 15 antineoplastic agents. Cell Pharmacol. 1994, 1, 279-285.
41. Delville, J. P.; Pradier, O.; Pauwels, O.; Van Onderbergen, A.; Kiss, R.; Feremans, W.; Capel, P. Comparative study of multi-drug resistance evaluated by means of the quantitative immunohistochemical detection of P-glycoprotein and the functional release of rhodamine 123. Am. J. Hematol. 1995, 49, 183-193.
42. Staroske, T.; Hennig, L.; Welzel, P. Synthesis and pharmacological properties of cardenolides substituted at the butenolide part. Tetrahedron 1998, 52, 12733-12744.
43. Bereta, J.; Cohen, M. C.; Bereta, M. Stimulatory effect of ouabain on VCAM-1 and iNOS expression in murine endothelial cells: involvement of NF-kappaB. FEBS Lett. 1995, 377, 21-25.
44. Aizman, O.; Uhlen, P.; Lal, M.; Brismar, H.; Apeira, A. Ouabain, a steroid hormone that signals with slow calcium oscillations. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 13420-13424.
45. Scheiner-Bobis, G.; Schoner, W. A fresh facet for ouabain action. Nat. Med. 2001, 7, 1288-1289.
46. Miyakawa-Naito, A.; Uhlen, P.; Lal, M.; Aizman, O.; Mikoshiba, K.; Brismar, H.; Zelenin, S.; Aperia, A. Cell signaling micro-domain with Na,K-ATPase and inositol 1,4,5-triphosphate receptor generates calcium oscillations. J. Biol. Chem. 2003, 278, 50355-50361.
47. Srenivasan, Y.; Sarkar, A.; Manna, S. K. Oleandrin suppresses activation of nuclear transcription factor-kappa B and activator protein-1 and potentiates apoptosis induced by ceramide. Biochem. Pharmacol. 2003, 66, 2223-2239.
48. Amit, S.; Ben-Neriah, Y. NF-κB activation in cancer: a challenge for ubiquitination-and proteasome-based therapeutic approach. Semin. Cancer Biol. 2003, 13, 15-28.
49. Ghosh, S.; May, M. J.; Kopp, E. B. NF-κappa B and Rel proteins: evolutionarily conserved mediators of immune response. Annu. Rev. Immunol. 1998, 16, 225-260.
50. Miyamoto, S.; Verma, I. M. REl/NF-κB/IκB story. Adv. Cancer Res. 1995, 55, 255-292.
51. Karin, M.; Ben-Neriah, Y. Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu. Rev. Immunol. 2000, 18, 621-663.
52. Whiteside, S. T.; Israel, A. I kappa B protein: structure, function and regulation. Semin. Cancer Biol. 1997, 8, 75-82.
53. Gilmore, T. D.; Koedood, M.; Piffat, K. A.; White, D. W. Rel/NF-kappaB.IkappaB proteins and cancer. Oncogene 1996, 13, 1367-1378.
54. Mijatovic, T.; Op De Beeck, A.; Van Quaquebeke, E.; Camby, I.; Dewelle, J.; Decaestecker, C.; de Launoit, Y.; Darro, F.; Kiss, R. Newly Identified Cardenolide Displays Potent In Vitro and In Vivo Anti-Tumor Activity in the Case of Experimental Human Non-Small-Cell-Lung Cancers (NSCLCs) by Overcoming Their Natural Chemotherapeutic Defenses. Clin. Cancer Res. (submitted for publication).
55. Sperandio, S.; de Belle, I.; Bredesen, D. E. An alternative, nonapoptotic form of programmed cell death. Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 14376-14381.
56. Okada, H.; Mak, T. W. Pathways of apoptotic and nonapoptotic death in tumour cells. Nat. Rev. Cancer 2004, 4, 592-603.
57. Stenkvist, B.; Bengtsson, E.; Dahlquist, B.; Eriksson, O.; Jarkrans, T.; Nordin, B. Cardiac glycosides and breast cancer, revisited. N. Engl. J.Med. 1982, 484, 483.
58. Stenkvist, B. Is digitalis a therapy for breast carcinoma? Oncol. Rep. 1999, 6, 493-496.
59. Manunta, P.; Hamilton, B. P.; Hamlyn, J. M. Structure-activity relationships for the hypertensinogenic activity of ouabain: role of the sugar and lactone ring. Hypertension 2001, 37, 472-477.